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H IV infection, pregnancy, and HAARTregimens represent different conditions thathave all been independently associated with
changes in serum lipids.1–3 With respect to
antiretroviral treatment, it is currently believed
that the risk of dyslipidemia may be higher in the
case of treatment with protease inhibitors (PIs)3 or
stavudine.4 Even if pregnancy is characterized by
important metabolic changes, little is known at
present about the evolution of lipid serum levels
during pregnancy in HIV-infected women and
about the effect of antiretroviral drugs on such
levels during pregnancy. Information on these
issues may be relevant for the care of pregnant
women with HIV.
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We used data from an ongoing national surveil-
lance study of pregnant women with HIV to define
serum lipid changes during pregnancy in HIV-in-
fected women and the effect of PIs and stavudine
on triglyceride and cholesterol serum levels during
all three trimesters of pregnancy.
Purpose: We investigated the evolution of serum lipid levels in HIV-infected
pregnant women and the potential effect of antiretroviral treatment during
pregnancy using data from a national surveillance study. Method: Fasting lipid
measurements collected during routine care in pregnancy were used, analyzing
longitudinal changes and differences in lipid values at each trimester by protease
inhibitors (PIs) and stavudine use. Multivariate analyses were used to control for
simultaneous factors potentially leading to hyperlipidemia. Study population
included 248 women. Results: Lipid values increased progressively and
significantly during pregnancy: mean increases between the first and third
trimesters were 141.6 mg/dL for triglycerides (p < .001), 60.8 mg/dL for total
cholesterol (p < .001), 13.7 mg/dL for HDL cholesterol (p < .001), and 17.8 mg/dL for
LDL cholesterol (p = .001). At all trimesters, women on PIs had significantly higher
triglyceride values compared to women not on PIs. The effect of PIs on cholesterol
levels was less consistent. Stavudine showed a dyslipidemic effect at first trimester
only. Multivariate analyses confirmed these observations and suggested a potential
role of other cofactors in the development of hyperlipidemia during pregnancy.
Conclusion: The changes observed point to the need to further explore the causes
and the clinical correlates of hyperlipidemia during pregnancy in women with HIV.
Key words: cholesterol, HIV, pregnancy, protease inhibitors, triglycerides
*A complete list of group members is found in the Appendix.
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METHOD
The National Program on Surveillance on
Antiretroviral Treatment in Pregnancy is an ongo-
ing national surveillance study established in Italy
in 2001 to collect information on the safety and
efficacy of antiretroviral treatment in pregnancy.
The study is observational, and the data collected
reflect routine clinical care at each participating
center. Only HIV-positive pregnant women are in-
cluded, and no indication is given for treatment of
HIV infection or prophylaxis for mother-to-child
transmission, which are defined by the treating
physician. Informed consent is required for all en-
rolled women, using a patient information sheet
that has received approval by the competent Ethics
Committee.
All the results reported here are based on the
data extracted from the general database on Janu-
ary 10, 2006. Lipid values were collected during
routine clinical visits in pregnancy at the partici-
pating centers. The levels of triglycerides and of
total and fractionated (HDL and LDL) cholesterol
were measured locally at each center, with samples
collected in fasting conditions. All the women with
triglyceride and/or cholesterol measurements
available at first trimester of pregnancy were con-
sidered for the purpose of this article.
Baseline quantitative variables were compared
using the t test for independent samples. Categori-
cal variables were compared using the Pearson chi-
square test. Differences in mean serum lipid values
between trimesters were analyzed by the t test for
paired samples. Antiretroviral treatment at each
trimester was categorized according to PI and
stavudine use or nonuse at the time of blood sam-
pling, and lipid levels were compared in women
receiving or not receiving stavudine or PIs at each
trimester by the t test for independent samples.
The occurrence of hyperlipidemia during preg-
nancy was assessed as the proportion of women at
each trimester with triglyceride values higher than
200 mg/dL and/or cholesterol values higher than
240 mg/dL, according to the NCEP ATP III thresh-
olds.5 Due to the effect of pregnancy in increasing
triglyceride levels, the proportion of women with
third trimester triglyceride values above 400 mg/
dL was also calculated. All the above thresholds
were used as outcome measures in univariate lo-
gistic regression analyses based on the following
independent variables: HCV and HBV status (posi-
tive vs. negative), age (≤32 vs. >32), and body mass
index collected at study entry, plus use or nonuse
of PIs, use or nonuse of stavudine, any ongoing
antiretroviral treatment, CD4 count (<250 vs.
≥250/mm3), and HIV-1 RNA viral load values
(<1000 vs. ≥1000 copies/mL) registered at the time
of blood sampling. We also performed multivariate
logistic regression analyses based on the same out-
comes in which only the covariates showing a sig-
nificance level below .15 in univariate analysis
were considered. All the analyses were performed
using the SPSS software, version 11.0.1, 2001 (SPSS
Inc., Chicago, USA).
RESULTS
As of January 10, 2006, 248 women had triglycer-
ide or cholesterol measurements available at the
first trimester of pregnancy (Table 1).
Overall, all serum lipids considered increased
steadily across the three trimesters of pregnancy
(Figure 1, Table 2). The increases between trimes-
ters were highly significant for all parameters (trig-
lycerides, total cholesterol, HDL and LDL choles-
terol; Table 3). Mean increases between first and
third trimesters were 141.6 mg/dL for triglycerides
(p < .001), 60.8 mg/dL for total cholesterol (p <
.001), 13.7 mg/dL for HDL cholesterol (p < .001),
and 17.8 mg/dL for LDL cholesterol (p = .001). The
total cholesterol/HDL cholesterol ratio (TC/HDL-
C) remained substantially unchanged during preg-
nancy (mean values at first, second, and third tri-
mester: 3.50, 3.32, and 3.50, respectively).
As expected, coverage with antiretroviral
therapy increased with the advancing of preg-
nancy (50.0%, 90.8%, and 98.1%, respectively, at
first, second, and third trimester), with a parallel
increase in use of PIs (22.4%, 40.1%, and 47.5%,
respectively). Use of stavudine, conversely, was
relatively constant (18.1%, 22.0%, and 22.0%, re-
spectively).
To assess the possible role of PIs and stavudine
on lipid concentrations, we first compared trigly-
ceride and cholesterol values between groups of
pregnant women taking and not taking such drugs
at each trimester. Women on PI treatment had sig-
nificantly higher triglyceride values at all trimes-
ters compared to women not on PI treatment at the
same time (Table 4).
Treatment with PIs had a less pronounced effect
on total cholesterol: as observed for triglycerides,
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Table 1.  General characteristics
Median Range
Age (years) at conception (n = 247) 33 19–43
Body mass index at conception (n = 210) 21.8 16.2–40.7
CD4 cells/mm3 at conception (n = 191) 495 23–1376
n %
Route of transmission (n = 245)
Sexual 172 70.2
IV drug use 46 18.8
Unknown 24 9.8
Transfusion/other 3 1.2
Nationality (n = 248)
Italian 185 74.6
Non-Italian 63 25.4
HIV CDC clinical status at conception (n = 244)
Asymptomatic 197 80.7
Symptomatic, non-AIDS 32 13.1
AIDS 15 6.1
Coinfections (n = 230)
HCV 63 27.4
HBV 30 13.1
On antiretroviral treatment at conception (n = 246)
Yes 150 61.0
No 96 39.0
Number of drugs at conception (n = 246)
None 96 39.2
Two 18 7.3
Three or more 132 53.5
Antiretroviral treatment history (n = 246)
Treatment-experienced 186 75.6
Treatment-naive 60 24.4
Indication for antiretroviral treatment (n = 220)
For the health of the mother 169 76.8
Only for the prevention of MTCT 51 23.2
Use of PIs
First trimester (n with information available = 241) 54 22.4
Second trimester (n with information available = 207) 83 40.1
Third trimester (n with information available = 200) 95 47.5
Use of stavudine
First trimester (n with information available = 232) 42 18.1
Second trimester (n with information available = 205) 45 22.0
Third trimester (n with information available = 205) 45 22.0
Note: MTCT = mother-to-child transmission; PIs = protease inhibitors.
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both groups showed a progressive increase from
first to third trimester, with consistently higher val-
ues at each trimester for PI-treated women. The
difference, however, was limited and did not reach
statistical significance at any trimester. No signifi-
cant differences in HDL cholesterol, in LDL choles-
terol, and in TC/HDL-C ratio at any trimester were
observed between women taking and not taking
PIs (data not shown).
To exclude that the higher triglyceride levels ob-
served in women receiving PIs were due to a gen-
eral dyslipidemic effect of antiretroviral therapy
(ARV), we performed a confirmatory analysis in
which women not on PIs were further divided into
two groups (women on non-PI–based ARV and
women not on treatment). This analysis confirmed
that the observed effect was PI specific: compared
to women on PIs, women on non-PI–based ARV
(mostly represented by three-drug regimens) had
significantly lower triglyceride levels at all trimes-
ters (112.7, 171.1, and 228.3 mg/dL, respectively; p
= .009, .021, and .001). Conversely, no significant
differences in triglyceride levels were observed be-
tween women on non-PI–based ARV treatment
Figure 1. Serum triglyceride and cholesterol levels (total cholesterol, HDL- and LDL-cholesterol) during pregnancy, by
trimester. Trig = triglycerides; C-TOT = Total cholesterol; C-HDL = HDL cholesterol; C-LDL = LDL cholesterol; Trim =
Trimester of pregnancy. Values are reported in mg/dL. Black lines indicate median values; the boxes indicate
interquartile range; the circles denote values with a distance from the median between 1.5 and 3 times the interquartile
distance; and asterisks indicate values with a distance from the median greater than 3 times the interquartile distance.
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and women not on ARV, who had levels at first
and second trimester of 97.4 and 153.4 mg/dL,
respectively (p >.05); no comparison was made at
third trimester for women not on ARV because
only four women were not receiving ARV at that
time.
A similar analysis based on stavudine use
showed an apparent dyslipidemic role of
stavudine at first trimester only, with higher values
of triglycerides (mean difference: 45.0 mg/dL, 95%
CI 6.8–83.4, p = .022) and total cholesterol (mean
difference: 19.5 mg/dL, 95% CI 2.3–36.7, p = .027)
among women taking this drug. This effect was not
present at the second and third trimesters, and
stavudine also showed no effect at any trimester on
cholesterol fractions (HDL and LDL cholesterol)
and on TC/HDL-C ratio (data not shown).
Overall, the occurrence of hypertriglyceridemia
and hypercholesterolemia according to the NCEP
thresholds was relatively common and appeared to
be increasingly frequent with the advancing of
pregnancy (66.9% and 47.3%, respectively, at third
trimester; Table 2).
Univariate logistic regression models suggested
a potential role of multiple factors on hyperlipi-
demia. To assess their independent role, multivari-
ate logistic regression analyses were performed.
Such analyses showed that at both first and second
trimesters use of PIs was significantly and inde-
pendently associated with triglyceride levels above
200 mg/dL, with a nine-fold increase in risk of
hypertriglyceridemia at first trimester and a two-
fold increase at second trimester, compared to non-
use of PIs (Table 5). At third trimester, this associa-
Table 2.  Lipid profile in HIV-positive women by trimester of pregnancy
First trimester Second trimester Third trimester
Triglycerides, mg/dL
Available, n 232 187 172
Mean 115 180 254
Median 94 166 233
Interquartile range 69–142 126–212 180–315
Range 33–532 42–452 46–750
Levels >200 mg/dL, n (%) 17 (7.3%) 57 (30.5%) 115 (66.9%)
Levels >400 mg/dL, n (%) 4 (1.7%) 5 (2.7%) 22 (12.8%)
Total cholesterol, mg/dL
Available, n 238 186 167
Mean 176 210 238
Median 172 204 235
Interquartile range 151–197 180–243 200–277
Range 84–372 88–379 106–430
Levels >240 mg/dL, n (%) 15 (6.3%) 49 (26.3%) 79 (47.3%)
HDL cholesterol, mg/dL
Available, n 138 120 103
Mean 55 67 71
Median 51 66 70
Interquartile range 43–66 52–78 59–82
Range 11–121 20–158 34–134
LDL cholesterol, mg/dL
Available, n 75 72 59
Mean 100 106 117
Median 98 104 121
Interquartile range 80–121 81–128 87–150
Range 39–216 40–188 42–189
xx
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tion showed a borderline level of significance (p =
.055). At the higher threshold of 400 mg/dL, use of
PIs was significantly and independently associated
with hypertriglyceridemia, with a five-fold in-
crease in risk at third trimester (Table 5).
The results of the multivariate analysis based on
cholesterol level above 240 mg/dL as the outcome
measure showed different associations at each tri-
mester (Table 5). No association was found be-
tween hypercholesterolemia and use of PIs at any
trimester.
DISCUSSION
Use of antiretroviral treatment during preg-
nancy is associated with several concerns, which
include potential teratogenicity, risk for the ex-
posed and uninfected newborn, possible reduced
efficacy of antiretroviral regimens in this particular
condition, and safety considerations for the
mother, including potentially increased risk of spe-
cific adverse events.
Our study provides information on a scarcely
Table 4.  Mean differences in cholesterol and triglycerides at each trimester by protease inhibitor (PI)
use
Average 95% CI
n difference for the
Mean value PI No PI (PI /no PI) (mg/dL) difference p
Triglycerides, mg/dL
First trimester 159.1 102.7 51/177 56.5 24.1–88.8 .001
Second trimester 201.8 167.4 77/103 34.3 09.2–59.4 .008
Third trimester 286.4 231.6 82/830 54.8 19.8–89.7 .002
Total cholesterol, mg/dL
First trimester 179.9 173.8 54/178 06.1 −5.6–17.9 .307
Second trimester 218.2 205.4 77/101 12.8 −2.0–27.6 .090
Third trimester 243.3 237.7 79/810 05.6 −12.3–23.4 .540
xx
Table 3.  Mean differences in lipid values between subsequent trimesters
Average difference 95% CI for the
Measurement Trimesters considered n  (mg/dL) difference p
Triglycerides From Tr. I to Tr. II 178 + 66.4 55.5–77.2 <.001
From Tr. II to Tr. III 160 + 70.4 57.1–83.8 <.001
From Tr. I to Tr. III 162 + 141.6 125.0–158.1 <.001
Total cholesterol From Tr. I to Tr. II 179 + 34.2 28.2–40.1 <.001
From Tr. II to Tr. III 153 + 24.4 18.7–30.1 <.001
From Tr. I to Tr. III 163 + 60.8 53.6–68.0 <.001
HDL cholesterol From Tr. I to Tr. II <97 + 13.1 9.2–17.0 <.001
From Tr. II to Tr. III <88 + 2.3 0.1–4.5 <.043
From Tr. I to Tr. III <86 + 13.7 10.0–17.4 <.001
LDL cholesterol From Tr. I to Tr. II <53 + 9.8 1.1–18.6  <.027
From Tr. II to Tr. III <46 + 8.2 1.9–14.5  <.012
From Tr. I to Tr. III <45 + 17.8 7.4–28.3 < .001
Note: Tr. = trimester.
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explored area: the general effect of pregnancy on
serum lipid levels in pregnant women with HIV and
the effects in pregnancy of some drugs and regi-
mens already known to be able to induce metabolic
changes outside pregnancy. We were able to assess
levels of cholesterol and triglycerides by trimester,
with a detailed description of the dynamic changes
observed during pregnancy in women receiving
antiretroviral regimens based on different drugs.
A first result of our investigation is the confirma-
tion that pregnancy has an important effect on trig-
lyceride and cholesterol values in HIV-positive
women, with a progressive increase from first to
third trimester. To our knowledge, this has not
been previously documented in the setting of HIV
infection. In the entire group, all the changes for
triglycerides and cholesterol were significant, and
they can be summarized for the last two trimesters
of pregnancy in an increase of roughly 70 mg/dL
per trimester for triglycerides and of roughly 30
mg/dL per trimester for total cholesterol.
The clinical implications of these findings are
uncertain, because of the scarcity of data on this
issue. In our study, total cholesterol values in-
creased significantly during pregnancy, but both
HDL cholesterol and LDL cholesterol increased
significantly, too. As a consequence, the TC/HDL-
C ratio, which is considered an important predic-
Table 5.  Variables independently associated to hyperlipidemia in a multivariate analysis
Adjusted odds
Outcome Variable ratio (AOR) 95% CI p
Triglycerides >200 mg/dL at Use of PIs 9.17 3.00–28.0 <.001
first trimester
Triglycerides >200 mg/dL at Use of PIs 2.04 1.05–3.96 <.036
second trimester
Triglycerides >200 mg/dL at Age above 32 years 2.74 1.32–5.70 <.007
second trimester
Triglycerides >200 mg/dL at BMI 1.15 1.03–1.29 <.015
third trimester
Triglycerides >200 mg/dL at Coinfection with 2.87 1.07–7.65 <.035
third trimester HBV
Triglycerides >400 mg/dL at Use of PIs 5.80 1.82–18.5 <.047
third trimester
Cholesterol >240 mg/dL at Use of d4T 4.97 1.41–17.5 <.012
first trimester
Cholesterol >240 mg/dL at CD4 cells >250 9.98 1.30–76.8 <.027
second trimester
Cholesterol >240 mg/dL at HIV-RNA below 2.52 1.07–5.96 <.035
second trimester 1000 copies/mL
Cholesterol >240 mg/dL at CD4 cells >250 3.82 1.00–14.5 <.05
third trimester
Cholesterol >240 mg/dL at Coinfection with 2.59 1.14–5.91 <.006
third trimester HCV
Note: PIs = protease inhibitors; BMI = body mass index; HBV = hepatitis B virus; d4T = stavudine; HCV = hepatitis C
virus.
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tive factor for cardiovascular disease in women,6
remained substantially unchanged. This observa-
tion is partly reassuring in a context of cardiovas-
cular risk assessment and mitigates the possible
concerns raised by the high frequency of hypercho-
lesterolemia.
The frequent occurrence of high levels of triglyc-
erides may also represent a concern. In the general
population, hypertriglyceridemia represents an in-
dependent risk factor for cardiovascular disease,7
and, if severe, may cause pancreatitis.8 Cases of
pancreatitis induced by severe hypertriglycer-
idemia have been reported in pregnant women,9
and early hypertriglyceridemia has been associ-
ated with subsequent development of gestational
diabetes mellitus10 and early-onset preeclampsia.11
In pregnant women with normal glucose tolerance,
triglyceride levels measured at midpregnancy or at
the third trimester of pregnancy were independent
predictors of neonatal birth weight, suggesting a
potential independent role on the development of
fetal macrosomia.12,13 Triglyceride levels, therefore,
can be associated with different pathological con-
ditions. Assessing the clinical correlates of
hypertriglyceridemia and of hypercholesterolemia
in HIV-positive pregnant women is beyond the
scope of this article; in future studies, we will as-
sess whether the metabolic changes persist after
pregnancy and whether such changes may predict
adverse pregnancy outcomes.
We demonstrated that PIs, which are commonly
used in pregnancy, have an important effect on
lipid profile, enhancing the hyperlipidemic effect
of pregnancy. Compared to women not taking PIs,
women receiving PIs had constantly higher values
of triglycerides at each trimester, with average dif-
ferences of about 35–50 mg/dL at different trimes-
ters. This finding was confirmed by multivariate
analyses at all trimesters. All these associations
were statistically significant and were quantified in
a nine-fold increase in risk at first trimester, in a
two-fold increase at second trimester (with 200
mg/dL as threshold), and in a five-fold risk in-
crease at third trimester (at the higher threshold of
400 mg/dL). We also demonstrated that this
dyslipidemic effect was not a consequence of
antiretroviral treatment in general, because both
direct comparisons and multivariate analyses
showed no role for non-PI–based antiretroviral
treatment in favoring hypertriglyceridemia. Data
on total cholesterol also suggest a similar effect of
PIs, although less pronounced.
Our data also point to the need to further explore
the metabolic effects associated with stavudine.
The use of this drug, even if less common com-
pared to PIs, was consistently associated with in-
creased values of triglycerides, with average differ-
ences in the range of 17–45 mg/dL. These
differences, however, reached statistical signifi-
cance at the first trimester only. Our data, there-
fore, though clearly suggestive of a specific role of
stavudine in increasing triglycerides during preg-
nancy, do not allow us to firmly establish it. This
issue deserves further investigation and could be
reassessed on a wider sample basis.
Both PIs and stavudine showed no significant
effect on HDL- or LDL-cholesterol values or on
TC/HDL-C value. The increased levels of total
cholesterol observed at the first trimester in women
taking stavudine also need confirmation on wider
samples, because a similar trend was not observed
in subsequent trimesters.
Multivariate analyses indicated other possible
predictors of dyslipidemia. Age was a significant
cofactor in hypertriglyceridemia at the second tri-
mester. Although increasing age is a possible factor
for metabolic disease and hyperlipidemia, we be-
lieve this finding should be considered cautiously,
given the absence of similar findings in the other
two trimesters.
The evolution of cholesterol levels also may be
relevant in the care of pregnant women with HIV.
In our study, cholesterol levels were affected pri-
marily by pregnancy, with no apparent effect of PIs
in multivariate analyses at all trimesters. The find-
ings concerning other potential cofactors of hyper-
cholesterolemia were less consistent, and appar-
ently different cofactors were identified at different
trimesters: use of stavudine at the first trimester,
low RNA levels at the second trimester, HCV
coinfection at the third trimester, and higher CD4
counts at the second and third trimesters. Even if
some rationale was found for all these findings, we
believe that confirmatory studies are needed to bet-
ter establish their role.
One limitation of our study is the relatively small
number of women receiving stavudine. This factor
may actually have prevented us from ascertaining
a statistically significant effect of stavudine on trig-
lycerides, which was clinically suggested by the
clear trend for higher levels observed in women
receiving the drug. It should be considered that use
of stavudine in pregnancy may be also relatively
less frequent compared to other drugs due to con-
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cerns regarding specific toxicities, such as lactic
acidosis in the mothers and mitocondrial disease in
the newborns.14,15 A greater number of cases col-
lected through a continued surveillance may en-
able us to reassess this issue in the future.
Among the strengths of our study is the size of
the sample, which is taken from a national study
involving more than 30 clinical centers. The num-
ber of women enrolled also allowed us to perform
analyses adjusted for multiple potentially predic-
tive factors, and all the data were collected in a
setting of clinical practice and not of clinical trials,
which may ensure a better evaluation of treatments
presently used in these settings.
It should also be considered that clinical trials,
even if able to guarantee more complete and accu-
rate information, are quite difficult to conduct in
pregnant women and, in any case, are unlikely to be
performed on such a large basis: our observational
study, therefore, may represent one of the few pos-
sible relevant sources of information on this subject.
The importance of our findings is likely to be
enhanced by the recent updates in treatment rec-
ommendations regarding nonnucleoside reverse
transcriptase inhibitors (NNRTIs), limiting the use
of these drugs in women of childbearing age be-
cause of possible teratogenicity (efavirenz) and of
CD4-level–dependent toxicity.16,17 Such limitations
are likely to lead to a preferential use of other
drugs, particularly PIs, in pregnant women. In this
context, we believe that our information may con-
tribute to a comprehensive assessment of potential
risks and benefits of different antiretroviral regi-
mens in pregnancy.
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